logo
Plus   Neg
Share
Email

FDA Approves Lilly's New Rapid-acting Insulin Lyumjev

Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration has approved Lyumjev, the company's new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.

Lyumjev is a novel formulation of insulin lispro, developed to speed the absorption of insulin into the blood stream and reduce A1C levels. Lyumjev controls high blood sugar levels after meals in adults with diabetes, similar to how natural insulin works after meals in people without diabetes.

Lyumjev is insulin lispro-aabc injection and comes in two strengths: U-100 (100 units per milliliter) and U-200 (200 units per milliliter).

Lyumjev will be included in the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance at all to fill their monthly prescription of Lyumjev for $35.

Lyumjev has been approved by regulatory authorities in several global markets, including Japan and the European Union in March 2020. Lilly is currently working to make Lyumjev available to adults with diabetes in the U.S. as quickly as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT